Sulglicotide
Also known as: Duodenal glycopeptide sulfate, Glypressin, Sulglycotide, Tepilta
Source Sulglicotide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Sulglicotide (also known as Glypressin in some contexts, but more specifically marketed as Tepilta) is a sulfated glycopeptide extracted from porcine duodenal mucosa. It is used primarily in the treatment of peptic ulcer disease and gastritis. It acts as a gastroprotective agent rather than an acid suppressor, reinforcing the mucosal defense mechanisms.
Mechanism of Action
Sulglicotide is a sulfated glycopeptide derived from duodenal mucosa that acts as a cytoprotective agent. It enhances the gastric mucosal barrier by stimulating mucus secretion, promoting prostaglandin synthesis, and inhibiting pepsin activity, thereby protecting the gastric epithelium from acid-induced damage.
Routes of Administration
Goals & Uses
- Mucosal cytoprotectionGastrointestinalModerate
- Pepsin inhibitionEnzyme InhibitionLow
- Gastritis managementGastrointestinalModerate
- Peptic ulcer treatmentGastrointestinalModerate
Contraindications
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Hypersensitivity to porcine-derived productsAllergy / ImmunologicalHigh
Adverse Effects
- Allergic reactionImmunologicRareImmune-mediated hypersensitivity response
- Abdominal discomfortGastrointestinalUncommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- DiarrheaGastrointestinalUncommonLoose or frequent stools
Drug Interactions
- AntacidsLow
- NSAIDsModerateMay increase renal risk in susceptible patients
Population Constraints
- Pediatric patientsAgeRelative
- Patients with porcine product allergyAllergyAbsolute
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Peptic ulcer disease, GastritisApproved in Italy and select European markets; not universally approved across all EU member states.
- United StatesUnapprovedNot approved by the FDA; not commercially available in the United States.
- United KingdomUnknownNot widely referenced in MHRA approved product lists; availability uncertain.
Approved in Italy and some other European and Asian markets for gastric and duodenal ulcer treatment. Not approved by the US FDA. Regulatory status varies widely by country.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Sulglicotide?
Sulglicotide (also known as Glypressin in some contexts, but more specifically marketed as Tepilta) is a sulfated glycopeptide extracted from porcine duodenal mucosa. It is used primarily in the treatment of peptic ulcer disease and gastritis. It acts as a gastroprotective agent rather than an acid suppressor, reinforcing the mucosal defense mechanisms.
What is Sulglicotide used for?
Sulglicotide is educationally associated with: Mucosal cytoprotection, Pepsin inhibition, Gastritis management, Peptic ulcer treatment. Educational only — not medical advice.
How is Sulglicotide administered?
Recorded routes of administration: Oral.
What are the potential side effects of Sulglicotide?
Reported adverse effects include: Allergic reaction, Abdominal discomfort, Nausea, Diarrhea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Sulglicotide?
Recorded contraindications: Pregnancy, Hypersensitivity to porcine-derived products. Consult a qualified clinician before use.